BioCentury
ARTICLE | Discovery & Translation

Science Spotlight: A FOXP3 regulator to enhance induced Tregs

BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more

April 5, 2025 12:26 AM UTC

A suppressor of the regulatory T cell master transcription factor FOXP3 identified by the lab of Treg pioneer Shimon Sakaguchi and collaborators at Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) provides a pathway to improve the stability and efficacy of Treg cell therapies for autoimmune diseases, particularly those generated by inducing Treg phenotypes in effector T cells, instead of relying on the isolation and expansion of a rare thymically derived “natural” Tregs.

The Nature paper authors performed a genome-wide CRISPR knockout screen with single-cell RNA readouts and simultaneous quantification of intracellular protein expression at single cell resolution, a method they dubbed Perturb-icCITE-seq. The screen identified the RBPJ-NCOR repressor complex, part of the Notch signaling pathway, as a negative regulator of FOXP3...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article